10-Q: Evofem Faces Liquidity Crisis Amidst Merger Efforts

Evofem Biosciences reports continued operating losses and significant liquidity concerns, relying on a pending merger with Aditxt and new product commercialization to sustain operations.

Summary

• Net product sales increased 16% to $4.825 million in the second quarter of 2025, but decreased 27% to $5.670 million for the six months ended June 30, 2025, compared to the prior year periods.
• Net loss for the second quarter of 2025 was $1.784 million, a shift from a $1.351 million net income in the second quarter of 2024.
• Year-to-date net loss for the six months ended June 30, 2025, was $0.828 million, an improvement from a $3.458 million loss in the prior year, largely due to a $5.6 million reduction in research and development expenses from trade payables negotiation.
• Operating expenses decreased for the six months ended June 30, 2025, primarily due to the research and development reduction and lower general and administrative costs, despite increased selling and marketing expenses.
• The company has a working capital deficit of $64.9 million and an accumulated deficit of $898.5 million as of June 30, 2025.
• Cash and cash equivalents were $0, with $0.748 million in restricted cash as of June 30, 2025.
• The company faces substantial doubt about its ability to continue as a going concern, with current liquidity insufficient for the next 12 months.
• Approximately 82% of trade payables were over 90 days past due as of June 30, 2025.
• The company's common stock was delisted from OTCQB to OTC Pink Current on April 23, 2025, due to minimum bid price non-compliance, and subsequently moved to OTCID on July 1, 2025.
• A key debt holder, Future Pak, LLC, has issued multiple Notices of Default, accelerating repayment of $107.0 million, which the company disputes.

Sentiment

Score: 2

Explanation: The company is in a precarious financial position with significant liquidity issues, a going concern warning, and ongoing debt defaults. While there are some positive product developments and Q2 revenue growth, the overall financial health and operational risks are severe.

Positives

• Reduced operating loss for both the three and six months ended June 30, 2025, compared to the prior year periods.
• Increased net product sales by 16% to $4.825 million in the second quarter of 2025 compared to the same period in 2024.
• Acquired global rights to SOLOSEC in July 2024 and successfully relaunched the brand in November 2024.
• Expanded into the Middle East and North Africa (MENA) region via licensing agreements for PHEXXI and SOLOSEC with Pharma 1 Drug Store.
• Received FDA approval for the PHEXXI re-branding name in April 2025.
• PHEXXI approval rates are consistently above 80% by payers, indicating strong market access.
• A new Phase 4 clinical trial for SOLOSEC, evaluating its efficacy and cost-effectiveness for trichomoniasis, is underway and funded directly by the National Institutes of Health (NIH).
• Negotiation of a portion of trade payables resulted in a $5.6 million reduction in research and development expenses for the six months ended June 30, 2025.

Negatives

• Substantial doubt exists about the company's ability to continue as a going concern, with liquidity resources insufficient to fund operations for the next 12 months.
• The company reported a significant working capital deficit of $64.9 million as of June 30, 2025.
• Accumulated deficit increased to $898.5 million as of June 30, 2025.
• Shifted from a net income of $1.351 million in Q2 2024 to a net loss of $1.784 million in Q2 2025.
• Year-to-date net product sales decreased by 27% to $5.670 million for the six months ended June 30, 2025, compared to the prior year.
• Net cash used in operating activities significantly increased to $2.359 million for the six months ended June 30, 2025, from $1.018 million in the prior year period.
• Common stock was delisted from OTCQB to OTC Pink Current due to non-compliance with the minimum bid price requirement.
• Future Pak, LLC, the holder of the Baker Notes, issued multiple Notices of Default, accelerating repayment of approximately $107.0 million, which the company is contesting.
• Approximately 82% of the company's trade payables were greater than 90 days past due as of June 30, 2025.
• Adjuvant's call option to purchase the Adjuvant Notes and Rights for $13.0 million expired unexercised on June 30, 2025.
• The company failed to meet the July 2024 deadline for changing the name of PHEXXI as part of a settlement agreement with TherapeuticsMD.

Risks

• Ability to continue as a going concern due to recurring losses and insufficient liquidity.
• Disruptions in the commercialization of PHEXXI or SOLOSEC and/or their supply chains.
• Potential legal actions and negative outcomes from the Notice of Default issued by Future Pak, LLC regarding the Baker Notes.
• Ability to remediate identified material weaknesses in internal controls and procedures.
• Ability to obtain necessary approvals for corporate actions, including stockholder and FINRA approvals.
• Ability to file Annual and Quarterly Reports on a timely basis.
• Ability to raise additional capital to fund operations if and as needed.
• Ability to achieve and sustain profitability.
• Compliance with the provisions and requirements of debt arrangements and avoidance of future defaults.
• Rate and degree of market acceptance of products.
• Requirement to change the name of PHEXXI and estimates regarding the timing and cost thereof.
• Potential for changes to current regulatory mandates requiring health insurance plans to cover FDA-approved contraceptive products without cost sharing.
• Ability to obtain or maintain third-party payer coverage and adequate reimbursement, and reliance on patients paying out-of-pocket.
• Potential substantial negative impact on contraception access and STI treatment, especially for low-income and uninsured women, after the passage of the One Big Beautiful Bill Act.
• Ability to protect and defend intellectual property position and reliance on third-party licensors.
• Ability to obtain additional patent protection for products.
• Dependence on third parties for the manufacture of products.
• Ability to expand the organization to accommodate potential growth.
• Ability to retain and attract key personnel.
• Uncertainty in fair value estimates for financial instruments due to reliance on management assumptions.
• Potential litigation from other vendors due to a high percentage of past due trade payables.
• Stockholder demands regarding alleged omissions of material information in proxy statements.

Future Outlook

The company anticipates it will continue to incur net losses for the foreseeable future. Management plans to meet cash flow needs in the next 12 months by generating recurring product revenue from PHEXXI and SOLOSEC, earning milestone payments from the Pharma 1 license agreement for SOLOSEC, restructuring current payables, and obtaining additional funding through the Amended and Restated Merger Agreement, non-dilutive financings, collaborations, partnerships, or other potential business combinations. The company expects to maintain a lean operating structure in 2025 but may increase marketing spend if resources become available.

Management Comments

• "We continue to focus on top-line growth while maintaining a lean operating structure."
• "We will continue to explore opportunities for organic growth, entry into new markets including those covered by our license and supply agreements with Pharma 1, and potential expansion of our product offerings beyond PHEXXI and SOLOSEC."
• "Management believes that the Company’s cash and cash equivalents as of June 30, 2025 are insufficient to fund operations for at least the next 12 months from the date on which this Quarterly Report on Form 10-Q is filed with the SEC."
• "The Company has concluded that these circumstances and the uncertainties associated with the Company’s ability to obtain additional equity or debt financing on terms that are favorable to the Company, or at all, and otherwise succeed in its future operations raise substantial doubt about the Company’s ability to continue as a going concern."
• "The Company strongly disagrees with the Designated Agent’s claim that an Event of Default has occurred. The Company intends to vigorously contest any attempt by the Designated Agent and the Purchasers to exercise their default rights and remedies under the Baker Bros. SPA."

Industry Context

The company operates in the women's sexual and reproductive health market, commercializing non-hormonal contraception (PHEXXI) and treatments for bacterial vaginosis and trichomoniasis (SOLOSEC). This market segment is significant, with over 23.3 million women in the U.S. not using hormonal contraception. The company is strategically leveraging its existing commercial infrastructure and physician relationships for SOLOSEC, which shares the same 'call point' as PHEXXI. The mention of the 'One Big Beautiful Bill Act' highlights potential regulatory impacts on contraception and STI treatment access, particularly for vulnerable populations. The NIH-funded Phase 4 trial for SOLOSEC indicates ongoing efforts to advance treatment options for common sexual health infections, aligning with broader public health initiatives.

Comparison to Industry Standards

• The filing does not provide specific comparable companies or projects with detailed results for direct comparison against global benchmarks.
• PHEXXI approval rates are consistently above 80% by payers, suggesting strong market access within its category.
• SOLOSEC demonstrated clinically and statistically significant efficacy in treating Bacterial Vaginosis (68% of patients did not require additional treatment) and a 92.2% cure rate for Trichomoniasis in women in clinical trials.
• ACOG and CDC guidelines include single-dose SOLOSEC for the treatment of Bacterial Vaginosis, and no longer recommend single-dose metronidazole to treat Trichomoniasis in women, indicating SOLOSEC's alignment with or potential superiority to some established treatment protocols.

Management Changes

Corporate Governance

Legal Proceedings

• A trademark dispute, TherapeuticsMD, Inc. v Evofem Biosciences, Inc., was settled on July 18, 2022, but the company failed to meet the terms by July 2024 (changing the name of PHEXXI). The company is currently working with TherapeuticsMD on resolution.
• Multiple letters were received from purported company stockholders demanding action regarding alleged omissions of material information in the preliminary proxy statement filed September 23, 2024, relating to the A&R Merger Agreement. The company believes these demands are without merit and is working to resolve them. The original proxy statement was withdrawn, and a new one was filed on July 24, 2025.
• Future Pak, LLC, as agent for the Baker Notes Purchasers, provided a Notice of Event of Default and Reservation of Rights on September 27, 2024, with subsequent amendments on October 27, 2024, and November 8, 2024. These notices claim an Event of Default and accelerate repayment of approximately $107.0 million. The company strongly disagrees with these claims and intends to vigorously contest them.
• The company settled a portion of its trade payables with numerous vendors, resulting in a $3.1 million reduction in trade payables and a $2.5 million reduction in accrued expenses. However, the company may receive additional trade payable demand letters from other vendors that could lead to potential litigation, as approximately 82% of trade payables were greater than 90 days past due as of June 30, 2025.

Related Party Transactions

• On March 20, 2025, the company entered into a License and Supply Agreement with Windtree Therapeutics, Inc., where Windtree will become a manufacturer and supplier of PHEXXI. Saundra Pelletier, the company's CEO, is also on the board of Windtree, making it a related party. No financial obligations have begun under this agreement as of the filing date.
• On April 8, 2025, and June 26, 2025, the company issued senior subordinated convertible notes (aggregate principal of $3.7 million) and warrants (242,257,742 shares) to Aditxt, Inc., the merger partner. Saundra Pelletier was appointed to Aditxt's Board of Directors on June 9, 2025, and will serve until her term expires.
• Aditxt provided funding to the company through the purchase of Series F-1 Preferred Shares, totaling $5.5 million across multiple tranches as part of the Amended and Restated Merger Agreement.
• Adjuvant Global Health Technology Fund, L.P. and Adjuvant Global Fund DE, L.P. (Adjuvant) granted Aditxt a call option to purchase the convertible Adjuvant Notes and Rights to receive common stock held by Adjuvant for $13.0 million. This call option expired on June 30, 2025.

Stakeholder Impact

• Shareholders face significant dilution risk from potential future capital raises and conversions of outstanding notes and warrants. The delisting from OTCQB to OTC Pink Current (and then OTCID) impacts liquidity and visibility of the stock. The 'going concern' warning poses a substantial risk to the value of their investment. The pending merger with Aditxt will fundamentally change the ownership structure and future prospects of the company.
• Employees may be impacted by the company's continued focus on maintaining a lean operating structure and potential further reductions in spending, although stock-based compensation is part of their remuneration.
• Customers benefit from the continued commercialization of PHEXXI and SOLOSEC, providing access to non-hormonal contraception and treatments for sexual health infections. Payer coverage and patient support programs are crucial for product affordability and access.
• Suppliers and creditors face significant risk, as 82% of trade payables were over 90 days past due, indicating severe payment difficulties. While some payables were settled, the potential for litigation from other vendors remains. Debt holders, particularly Future Pak, LLC, are actively pursuing default remedies, which could lead to accelerated repayment demands or asset claims.

Next Steps

• Generate recurring product revenue from PHEXXI and SOLOSEC.
• Earn milestone payments by achieving certain regulatory milestones under the License and Supply Agreement with Pharma 1 for SOLOSEC.
• Further restructure current payables.
• Obtain additional funding pursuant to the Amended and Restated Merger Agreement.
• Seek non-dilutive financings, collaborations, or partnerships with other companies, including license agreements for PHEXXI and/or SOLOSEC in the U.S. or foreign markets.
• Explore other potential business combinations.
• Advance PHEXXI re-branding plans and timeline following FDA approval of the new name.
• Vigorously contest any attempt by Future Pak, LLC to exercise default rights and remedies under the Baker Bros. SPA.
• Continue to work with TherapeuticsMD on resolution of the settlement issue regarding the PHEXXI name change.
• Hold a special meeting for stockholders to approve the Aditxt merger on or prior to September 26, 2025.
• The Amended and Restated Certificate of Designations of Series E-1 Convertible Preferred Stock will become effective on September 30, 2025.
• Pharma 1 is on track to file for regulatory approval of SOLOSEC in the UAE in the third quarter of 2025.
• Company expects to purchase approximately $0.8 million in SOLOSEC inventory in the remainder of 2025 and $1.9 million in 2026 under the transition services agreement.

Key Dates

Recommendation

The company faces severe financial distress, evidenced by the 'going concern' warning, insufficient liquidity for the next 12 months, and a substantial working capital deficit. The ongoing dispute with a major debt holder (Future Pak, LLC) over a $107 million accelerated repayment, coupled with 82% of trade payables being over 90 days past due, indicates a critical cash crunch. While the Aditxt merger and recent capital raises offer some short-term relief, they are insufficient to resolve the fundamental liquidity issues and come with significant dilution. The delisting from OTCQB further reduces market visibility and liquidity. The company's ability to continue operations is highly uncertain, making it a high-risk investment with significant downside potential.

Keywords

Evofem Biosciences, PHEXXI, SOLOSEC, women's health, contraception, bacterial vaginosis, trichomoniasis, biopharmaceutical, SEC filing, 10-Q, financial results, liquidity, going concern, Aditxt merger, debt default, OTC Markets, pharmaceutical, reproductive health